Relationship between serum lipoprotein ratios and insulin resistance in obesity.
Increased serum concentrations of LDL-cholesterol (LDL-C)  are atherogenic (4, 5), whereas increased HDL-cholesterol (HDL-C) is considered cardioprotective (5, 6). Increased serum concentrations of triglycerides (TGs) have also been recognized as a risk factor for cardiovascular disease (7,8). However, several epidemiologic studies demonstrated that the total cholesterol (TC)/HDL-C and the LDL-C/HDL-C ratios are better predictors of atherosclerosis and cardiovascular disease than any other single lipid marker (9-11). Likewise, the TG/HDL-C ratio was demonstrated to be as significant a predictor of cardiovascular disease as the two other lipid ratios (7).
The better ability of lipid ratios to predict cardiovascular disease compared with single lipid markers is of particular clinical relevance and can be possibly explained by association of lipid ratios with a cluster of cardiovascular risk factors that are at least in part unrelated to cholesterol metabolism (12). The TC/HDL-C ratio was shown to correlate negatively with rates of insulin-stimulated glucose disposal in a small group of healthy individuals (13). Subsequently, nondiabetic individuals who were of normal weight or overweight and had an increased TC/HDL-C ratio were shown to exhibit resistance to insulin-stimulated glucose disposal and to have higher blood pressure, increased TG concentrations, and hyperinsulinemia; each of these factors is part of the metabolic syndrome and is an independent risk factors for cardiovascular disease (12).
Increased TG/HDL-C ratios are able to identify insulin-resistant overweight individuals with normal glucose tolerance and are markers of insulin resistance with specificities and sensitivities similar to those for fasting plasma insulin concentration (14). Increased TG/HDL-C ratios also indicate the presence of atherogenic small, dense LDL particles (15,16) and could serve as a good predictor of myocardial infarction (7) and the presence of coronary atherosclerotic lesions (17). Furthermore, low serum HDL-C combined with increased serum TG concentrations predict the development of type 2 diabetes mellitus (18).
The relationship between these lipid ratios and insulin sensitivity has not been examined exclusively in an obese population that includes patients with different glucose tolerance status but excludes patients with other endocrine or metabolic disorders. The present study therefore aimed to assess whether the TC/HDL-C, LDL-C/HDL-C, and TG/HDL-C ratios relate to surrogate estimates of insulin sensitivity in an obese population and whether these relationships vary across categories of glucose tolerance. Participants and Methods
Individuals (n = 132) with a body mass index >30 kg/[m.sup.2] who had been referred to the endocrine outpatient service were examined. None of them was previously known to have either diabetes mellitus or impaired glucose tolerance or was taking hypoglycemic agents. Thirty-four individuals were excluded from further analysis because of treatment with lipid-lowering drugs (n = 10), hypothyroidism (n = 4), hyperthyroidism (n = 2), Cushing syndrome (n = 4), steroid therapy (n = 3), adrenal incidentalomas (n = 7), pheochromocytoma, primary hyperparathyroidism, hyperprolactinemia, or cyclosporine therapy after kidney transplantation (n = 1 for each). All procedures were performed according to the Helsinki Declaration of 1975 as revised in 1996 and according to guidelines of Good Clinical Practice.
After an overnight fast, an indwelling catheter was inserted at 0800 into an antecubital vein, and a baseline blood sample was obtained to determine fasting concentrations of plasma glucose and of serum insulin, C-peptide, TC, HDL-C, and TGs. All participants received a standard glucose solution containing 75 g of glucose (GlucoDrink 75; Roche Diagnostics). Blood samples for the measurement of plasma glucose and serum insulin and C-peptide concentrations were taken at 60, 90, and 120 min after glucose ingestion.
Participants were classified as having diabetes when the venous fasting plasma glucose concentration was [greater than or equal to]1260 mg/L and/or the 120-min plasma glucose concentration during the oral glucose tolerance test was [greater than or equal to]2000 mg/L. Impaired fasting glycemia was diagnosed when the fasting plasma glucose concentration was greater than or equal to 1100 mg/L but less than 1260 mg/L and the 120-min plasma glucose concentration during the oral glucose tolerance test was <1400 mg/L. Impaired glucose tolerance was diagnosed when the fasting plasma glucose concentration was <1260 mg/L and the 120-min plasma glucose concentration during the oral glucose tolerance test was greater than 1400 mg/L but less than 2000 mg/L (19).
Glucose was measured in venous fluoride EDTA plasma by the hexokinase method. Insulin (Adaltis) and C-peptide (PerkinElmer) concentrations were measured in serum by commercially available RIAs. Serum TC, HDL-C, and TG concentrations were determined enzymatically in the routine laboratory (20, 21). Serum LDL-C was calculated according to the Friedewald formula. One individual with serum TG >4000 mg/L was excluded from data analysis because use of the Friedewald formula is not applicable under these conditions.
Insulin sensitivity was calculated both in the fasting state and during the oral glucose tolerance test.
For the former, the quantitative insulin sensitivity check index (QUICKI) was used and calculated as the inverse of the sum of the logarithmic transformation of fasting concentrations of serum insulin and plasma glucose (22). This index has previously been shown to be a surrogate measure of insulin sensitivity, given the significant correlation with glucose disposal during euglycemic hyperinsulinemic glucose clamp tests (22-24).
The oral glucose insulin sensitivity index (OGIS; ML x [m.sup.-2] x [min.sup.-1]) was used as a descriptor of dynamic insulin sensitivity during the oral glucose tolerance test (25). This index has also been shown to positively correlate with glucose clearance obtained during hyperinsulinemic euglycemic glucose clamp tests in lean, obese, and type 2 diabetic individuals and is used as another surrogate measure of insulin sensitivity (25, 26). The OGIS is calculated according to a model-derived formula that includes the oral glucose dose; the body surface area; six fixed rate constants; the measured plasma concentrations of glucose at 0, 90, and 120 min; and the measured concentration of serum insulin at 0 and 90 min during the oral glucose tolerance test (25).
The relationship between both surrogate measures of insulin sensitivity and direct measures of insulin sensitivity have previously been shown to vary only slightly between obese individuals with normal and impaired glucose tolerance, first-degree relatives of patients with type 2 diabetes, and overweight to obese type 2 diabetic patients (23-25).
All statistical analyses were performed using SPSS 11.0 software (SP55 Inc.). Data are presented as means (SE).
Comparisons between groups of glucose tolerant, impaired glucose tolerant, and type 2 diabetic individuals were performed with one-way ANOVA with Tukey correction for several comparisons. Linear correlations are Pearson product-moment correlations.
To exclude possible effects of age and body mass index on the relationship between the three lipid ratios and the two indices of insulin sensitivity, multiple linear regression analyses were performed. QUICKI or OGIS was entered as the dependent variable, and age, body mass index, and the respective lipid ratio were entered as predictors. Partial correlation coefficients of the lipid ratios with QUICKI and OGIS from these analyses are presented. P <0.05 was considered to indicate a statistically significant difference.
CLINICAL CHARACTERISTICS AND GLUCOSE TOLERANCE
On the basis of the oral glucose tolerance test, 56 (58%) individuals were glucose tolerant, 22 (23%) exhibited previously unknown impaired glucose tolerance, and 19 (20%) were newly diagnosed with overt diabetes mellitus. Interestingly, none of the participants fulfilled the criteria for the diagnosis of impaired fasting glycemia. The clinical characteristics, fasting serum lipid profiles, and calculated lipid ratios are summarized in Table 1. The individuals newly diagnosed with type 2 diabetes mellitus were older than individuals with normal glucose tolerance (P <0.01), whereas mean ages of the individuals with normal and impaired glucose tolerance were comparable (P = 0.175). Height, weight, body mass index, and body surface area also did not differ among the three groups.
[FIGURE 1 OMITTED]
FASTING SERUM LIPID PROFILE AND LIPID RATIOS
TC, HDL-C, and LDL-C concentrations did not differ among individuals who were glucose tolerant, had impaired glucose tolerance, or had type 2 diabetes (Table 1). Compared with individuals with normal glucose tolerance, patients with impaired glucose tolerance (P <0.005) had higher TG values; these values also tended to be higher in patients with type 2 diabetes (P = 0.072). Neither the TC/HDL-C (P = 0.134) nor the LDL-C/ HDL-C ratio (P = 0.279) differed among the groups. Individuals with impaired glucose tolerance had ~1.5-fold higher TG/HDL-C ratios (P <0.05) than did individuals who were glucose tolerant. The TG/HDL-C ratio was not different between glucose-tolerant individuals and patients with type 2 diabetes.
CONCENTRATIONS OF GLUCOSE, INSULIN, AND CPEPTIDE DURING THE ORAL GLUCOSE TOLERANCE TEST
Concentrations of plasma glucose, serum insulin, and serum C-peptide during the oral glucose tolerance test in individuals with normal glucose tolerance, individuals with impaired glucose tolerance, and individuals with type 2 diabetes are shown in Fig. 1. By definition, plasma glucose concentrations in response to the oral glucose challenge were highest in patients with type 2 diabetes and lowest in glucose-tolerant individuals. Serum insulin and C-peptide responses were generally highest in individuals with impaired glucose tolerance and lowest in individuals with normal glucose tolerance.
INSULIN SENSITIVITY IN THE PATIENT GROUPS
Mean (SE) fasting insulin sensitivity indices (QUICKI) did not differ between patients with type 2 diabetes and individuals with impaired glucose tolerance [0.290 (0.002) for individuals with impaired glucose tolerance vs 0.281 (0.005) for patients with type 2 diabetes; P = 0.198] but were higher in individuals with normal glucose tolerance [0.302 (0.005)] compared with both individuals with impaired glucose tolerance (P <0.05) and patients with type 2 diabetes (P <0.001). Dynamic insulin sensitivity (CGIS) was lowest in patients with type 2 diabetes [256 (12) mL x [m.sup.-2] x [min.sup.-1]] compared with individuals with impaired glucose tolerance [293 (9) mL x [m.sup.-2] x [min.sup.-1]; P <0.05] and glucose-tolerant individuals [343 (7) ML x [m.sup.-2] x [min.sup.-1]; P <0.01] and was lower in individuals with impaired glucose tolerance compared with individuals with normal glucose tolerance (P <0.05).
CORRELATION ANALYSIS BETWEEN LIPID RATIOS AND MEASURES OF INSULIN SENSITIVITY
The relationship between the three lipid ratios and both surrogate measures of insulin sensitivity was assessed within the groups of individuals who had normal glucose tolerance, had impaired glucose tolerance, or had type 2 diabetes (Table 2). Neither the TC/HDL-C nor the LDLC/HDL-C ratio showed any significant relationships to both indices of insulin sensitivity in individuals who had normal glucose tolerance, had impaired glucose tolerance, or had type 2 diabetes.
The TG/HDL-C ratio negatively correlated with fasting insulin sensitivity in glucose-tolerant individuals and also tended (P [less than or equal to]0.1) to be negatively correlated with fasting and dynamic indices of insulin sensitivity in individuals with impaired glucose tolerance. No relationship between the TG/HDL-C ratio and measures of insulin sensitivity was found in the group with type 2 diabetes. When individuals with normal and impaired glucose tolerance were combined, correlation analysis revealed a negative relationship between TG/HDL-C ratios and indices of fasting insulin sensitivity (QUICKI, r = -0.370; P <0.001; Fig. 2A). This also was true for the relationship between the TG/HDL-C ratios and indices of dynamic insulin sensitivity (OGIS, r = -0.333; P <0.005; Fig. 2B).
[FIGURE 2 OMITTED]
These data show that the relationship between lipid ratios and insulin sensitivity varies between groups with different glucose tolerance status in an exclusively obese population (body mass index range, 30-57 kg/[m.sup.2]). Only the TG/HDL-C ratio correlated negatively with surrogate measures of insulin sensitivity in nondiabetic individuals but not in patients with type 2 diabetes mellitus.
The groups were comparable with regard to measures of adiposity, such as body mass index and body surface area. Fasting serum TG concentrations were ~40% higher in individuals with impaired glucose tolerance and also tended to be ~27% higher in patients with type 2 diabetes, whereas TC and LDL-C values were similar in all groups. This is in line with the positive association between serum TG concentrations and insulin resistance (27-30) and the unchanged serum concentrations of TC and LDL-C in insulin-resistant states (14, 28, 31-36).
The relationships between the three lipid ratios (TC/ HDL-C, LDL-C/HDL-C, TG /HDL-C) and both surrogate measures of insulin sensitivity were analyzed with multiple linear regression analyses, which allowed us to exclude the confounding effects of age and body mass index on these relationships. TC/HDL-C ratios were similar in all groups and not correlated with QUICKI and OGIS. Interestingly, two previous studies that both used a specific measure of insulin sensitivity demonstrated that increased TC/HDL-C ratios are associated with insulin resistance in individuals whose weight is normal (12,13) and negatively correlate with rates of insulin-stimulated glucose disposal in lean nondiabetic individuals (13). Although the present study might suggest that these relationships do not hold true in severe obesity, the small number of patients limits the statistical power and inference from these data. The LDL-C/HDL-C ratios were comparable and exhibited no relationships with surrogate measures of insulin sensitivity. Again the limited number of patients does not exclude the possibility of such relationships.
In the present study, we found that the TG/HDL-C ratio was ~40% higher in individuals with impaired glucose tolerance. In individuals with normal glucose tolerance, the TG/HDL-C ratio was related closely to QUICKI and less to OGIS, in particular when corrected for the confounding effects of age and body mass index. In individuals with impaired glucose tolerance, correlation coefficients between surrogate measures of insulin sensitivity and TG/HDL-C ratios were similar or higher than in glucose-tolerant individuals. These relationships achieved only borderline statistical significance, which most likely resulted from the small number of individuals with impaired glucose tolerance. When individuals with normal and impaired glucose tolerance were combined, the TG/HDL-C ratio negatively correlated with both surrogate measures of insulin sensitivity. The authors of a recent study with a larger cohort reported that TG concentrations or the TG/HDL-C ratio offer the most practical approach to identify insulin resistance in overweight nondiabetic volunteers (14). The present study extends these findings to a severely obese nondiabetic population (mean body mass index, ~38 vs ~29 kg/[m.sup.2]) comprising patients with normal and impaired glucose tolerance. In addition, the present study was performed in a cohort exhibiting marked insulin resistance with TG/HDL-C ratios higher than the TG/HDL-C cutoff values for detecting insulin resistance (14). Despite the similar efficacy for detecting insulin resistance, the more consistent association of TG/HDL-C compared with TG concentrations makes this ratio a promising marker of insulin resistance. Moreover, the TG/HDL-C ratio is associated with a higher risk for myocardial infarction than TG concentrations in a population including 8-14% diabetic patients (7). These data suggest that the TG/HDL-C ratio may serve as a marker that is easy to determine and links insulin resistance and cardiovascular risk in nondiabetic individuals (14). Of note, we found no correlation between TG/HDL-C ratio and either QUICKI or OGIS in patients with type 2 diabetes mellitus.
Several limitations must be considered in the interpretation of the results: (a) as stated above, the number of patients per group was rather small; (b) patients with type 2 diabetes were older than individuals with normal glucose tolerance, which, however, did not influence the results of the statistical evaluation after correction for age; and (c) gender differences in the relationship of lipid ratios and insulin sensitivity may exist but could not be addressed appropriately in the present study. Of note, McLaughlin et al. (14) did not detect any interaction between sex and the ability of the TG/HDL-C ratio to predict insulin resistance in 127 men and 131 women (14).
In conclusion, this study demonstrates that only the TG/HDL-C ratio positively correlates with insulin resistance in severely obese nondiabetic individuals but not in patients with overt diabetes. Our data therefore support recent findings in overweight glucose-tolerant individuals, indicating that the TG/HDL-C ratio serves as an easily available laboratory marker for identifying insulin resistance (14).
This study was supported in part by the Austrian Science Foundation (FWF; P15656), the European Foundation for the Study of Diabetes (EFSD; Novo Nordisk Type 2 diabetes grant), and the Herzfelder Family Trust (to M.R.). This study is also part of an ongoing cooperation between the Division of Endocrinology and Metabolism of the 3rd Department of Internal Medicine of the Medical University of Vienna and the Metabolic Unit of ISIB-CNR (formerly LADSEB).
Received May 19, 2004; accepted September 8, 2004. Previously published online at DOI: 10.1373/clinchem.2004.037556
(1.) Kopelman PG. Obesity as a medical problem. Nature 2000;404: 635-43.
(2.) Meigs JB. Epidemiology of the metabolic syndrome, 2002. Am J Manag Care 2002;8:S283-6.
(3.) Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
(4.) Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J 1986; 112:825-36.
(5.) Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256: 2835-8.
(6.) Gordon T, Castelli WP, Hjortland MC, Kannel WB, DawberTR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
(7.) Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997;96:2520-5.
(8.) Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
(9.) Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-7.
(10.) Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
(11.) Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285: 2481-5.
(12.) Jeppesen J, Facchini FS, Reaven GM. Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant. J Intern Med 1998;243:293-8.
(13.) Garg A, Helderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metabolism 1988;37:982-7.
(14.) McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-9.
(15.) Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003;10:186-91.
(16.) Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34:583-8.
(17.) Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873-80.
(18.) Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
(19.) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Geneva: WHO/ NCD/NCS/99.2, 1999.
(20.) Kattermann R, Jaworek D, Moller G, Assmann G, Bjorkhem I, Svensson L, et al. Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem 1984;22: 245-51.
(21.) Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated [alpha]-cyclodextrin. Clin Chem 1995;41:717-23.
(22.) Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
(23.) Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 2003;26:2426-32.
(24.) Rabasa-Lhoret R, Bastard JP, Jan V, Ducluzeau PH, Andreelli F, Guebre F, et al. Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states. J Clin Endocrinol Metab 2003;88:4917-23.
(25.) Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-48.
(26.) Kanauchi M. Validation of the oral glucose insulin sensitivity index to assess insulin sensitivity in Japanese subjects for use in clinical practice. Eur J Clin Invest 2003;33:1022-3.
(27.) Moro E, Gallina P, Pais M, Cazzolato G, Alessandrini P, Bittolo-Bon G. Hypertriglyceridemia is associated with increased insulin resistance in subjects with normal glucose tolerance: evaluation in a large cohort of subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes. Metabolism 2003;52:616-9.
(28.) Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
(29.) Laakso M, Pyorala K, Voutilainen E, Marniemi J. Plasma insulin and serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetic and non-diabetic subjects. Am J Epidemiol 1987;125:611-21.
(30.) Cambien F, Warnet JM, Eschwege E, Jacqueson A, Richard JL, Rosselin G. Body mass, blood pressure, glucose, and lipids. Does plasma insulin explain their relationships? Arteriosclerosis 1987; 7:197-202.
(31.) Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
(32.) Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-28.
(33.) Temelkova-Kurktschiev T, Hanefeld M. The lipid triad in type 2 diabetes-prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 2004;112:75-9.
(34.) Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570-81.
(35.) Wilson PW, Grundy SM. The metabolic syndrome: a practical guide to origins and treatment: part II. Circulation 2003;108:1537-40.
(36.) Karhapaa P, Voutilainen E, Kovanen PT, Laakso M. Insulin resistance in familial and nonfamilial hypercholesterolemia. Arterioscler Thromb 1993;13:41-7.
ATTILA BREHM,  GEORG PFEILER,  GIOVANNI PACINI,  HEINRICH VIERHAPPER,  and MICHAEL RODEN [1,3] *
 Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
 Metabolic Unit, Institute of Biomedical Engineering (ISIB-CNR), Padova, Italy.
 First Medical Department, Hanusch Hospital, Vienna, Austria.
* Address correspondence to this author at: First Medical Department, Hanusch Hospital, Heinrich Collin Strasse 30, A-1140 Vienna, Austria. Fax 43-1-91021-85019; e-mail email@example.com.
 Nonstandard abbreviations: LDL-C and HDL-C, LDL- and HDL-cholesterol, respectively; TG, triglyceride; TC, total cholesterol; QUICKI, quantitative insulin sensitivity check index; and OGIS, oral glucose insulin sensitivity index.
Table 1. Clinical characteristics and fasting serum concentrations of TC, HDL-C, LDL-C, and TGs in individuals with normal or impaired glucose tolerance and patients with type 2 diabetes mellitus. (a) NGT (b) IGT n (F/M) 56 (35/21) 22 (16/6) Age, years 39 (2) 46 (3) Body mass 37.5 (0.7) 36.4 (1.0) index, kg/[m.sup.2] Body surface 2.19 (0.03) 2.13 (0.06) area, [m.sup.2] TC, mg/L 2084 (52) 2246 (68) HDL-C, mg/L 504 (18) 474 (19) LDL-C, mg/L 1311 (46) 1394 (67) TGs, mg/L 1350 (67) 1891 (174) (d) TC/HDL-C ratio 4.33 (0.14) 4.90 (0.24) LDL-C/HDL-C 2.73 (0.11) 3.04 (0.20) ratio TG/HDL-C ratio 3.01 (0.25) 4.25 (0.48) (d) T2DM P n (F/M) 19 (12/7) Age, years 51 (3)c <0.005 Body mass 38.7 (1.0) 0.376 index, kg/[m.sup.2] Body surface 2.18 (0.06) 0.575 area, [m.sup.2] TC, mg/L 2063 (84) 0.179 HDL-C, mg/L 489 (26) 0.607 LDL-C, mg/L 1231 (78) 0.305 TGs, mg/L 1716 (154) <0.050 TC/HDL-C ratio 4.44 (0.28) 0.134 LDL-C/HDL-C 2.65 (0.21) 0.279 ratio TG/HDL-C ratio 3.93 (0.53) 0.050 (a) Data are means (SE), except for number and gender of individuals in each group. (b) NGT, normal glucose tolerance; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus. (c,d) Significant differences (P 0.05) between groups (ANOVA, post hoc Tukey correction): (c) T2DM vs NGT; (d) IGT vs NGT. Table 2. Pearson product moment correlation coefficients (r) and age- and body mass index-corrected partial correlation coefficients ([r.sub.partial]) between the three lipid ratios and surrogate measures of fasting (QUICKI) and dynamic (OGIS) indices of insulin sensitivity in obese individuals with normal glucose tolerance, impaired glucose tolerance, or type 2 diabetes. QUICKI Ratio Group r P [r.sub.partial] P TC/HDL-C NGT (a) -0.152 NS (b) -0.161 NS IGT -0.330 0.13 -0.193 NS T2DM 0.132 NS 0.242 NS LDL/HDL-C NGT -0.018 NS -0.032 NS IGT -0.212 NS -0.084 NS T2DM 0.272 NS 0.440 0.10 TG/HDL-C NGT -0.396 (c) 0.002 -0.400 (c) 0.003 IGT -0.399 0.066 -0.323 0.094 T2DM -0.155 NS -0.188 NS OGIS Ratio r P [r.sub.partial] P TC/HDL-C -0.145 NS -0.158 NS 0.013 NS 0.076 NS -0.070 NS -0.050 NS LDL/HDL-C -0.094 NS -0.100 NS 0.195 NS -0.274 NS -0.084 NS -0.081 NS TG/HDL-C -0.203 0.13 -0.235 0.086 -0.375 0.086 -0.365 0.10 -0.020 NS 0.026 NS (a) NGT, normal glucose tolerance; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus. (b) NS, not significant (P [greater than or equal to]0.2). (c) Correlations considered significant at P <0.05.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Lipids, Lipoproteins, and Cardiovascular Risk Factors|
|Author:||Brehm, Attila; Pfeiler, Georg; Pacini, Giovanni; Vierhapper, Heinrich; Roden, Michael|
|Date:||Dec 1, 2004|
|Previous Article:||Distribution spectrum of paraoxonase activity in HDL fractions.|
|Next Article:||Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography-tandem mass...|